School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, Australia.
School of Pathology and Laboratory Medicine, University of Western Australia, Nedlands, Australia.
J Bone Miner Res. 2016 Jun;31(6):1258-74. doi: 10.1002/jbmr.2786. Epub 2016 Feb 16.
Injured growth plate is often repaired by bony tissue causing bone growth defects, for which the mechanisms remain unclear. Because neurotrophins have been implicated in bone fracture repair, here we investigated their potential roles in growth plate bony repair in rats. After a drill-hole injury was made in the tibial growth plate and bone, increased injury site mRNA expression was observed for neurotrophins NGF, BDNF, NT-3, and NT-4 and their Trk receptors. NT-3 and its receptor TrkC showed the highest induction. NT-3 was localized to repairing cells, whereas TrkC was observed in stromal cells, osteoblasts, and blood vessel cells at the injury site. Moreover, systemic NT-3 immunoneutralization reduced bone volume at injury sites and also reduced vascularization at the injured growth plate, whereas recombinant NT-3 treatment promoted bony repair with elevated levels of mRNA for osteogenic markers and bone morphogenetic protein (BMP-2) and increased vascularization and mRNA for vascular endothelial growth factor (VEGF) and endothelial cell marker CD31 at the injured growth plate. When examined in vitro, NT-3 promoted osteogenesis in rat bone marrow stromal cells, induced Erk1/2 and Akt phosphorylation, and enhanced expression of BMPs (particularly BMP-2) and VEGF in the mineralizing cells. It also induced CD31 and VEGF mRNA in rat primary endothelial cell culture. BMP activity appears critical for NT-3 osteogenic effect in vitro because it can be almost completely abrogated by co-addition of the BMP inhibitor noggin. Consistent with its angiogenic effect in vivo, NT-3 promoted angiogenesis in metatarsal bone explants, an effect abolished by co-treatment with anti-VEGF. This study suggests that NT-3 may be an osteogenic and angiogenic factor upstream of BMP-2 and VEGF in bony repair, and further studies are required to investigate whether NT-3 may be a potential target for preventing growth plate faulty bony repair or for promoting bone fracture healing. © 2016 American Society for Bone and Mineral Research.
生长板损伤后常由骨组织修复,导致骨生长缺陷,但具体机制尚不清楚。神经生长因子在骨骨折修复中起作用,因此我们在此研究其在大鼠生长板骨修复中的潜在作用。胫骨生长板和骨钻孔损伤后,神经生长因子 NGF、BDNF、NT-3 和 NT-4 及其 Trk 受体的损伤部位 mRNA 表达增加。NT-3 和其受体 TrkC 的诱导作用最强。NT-3 定位于修复细胞,而 TrkC 则在损伤部位的基质细胞、成骨细胞和血管细胞中观察到。此外,全身 NT-3 免疫中和减少了损伤部位的骨量,也减少了损伤生长板的血管化,而重组 NT-3 治疗促进了骨修复,增加了成骨标志物和骨形态发生蛋白 2(BMP-2)的 mRNA 水平,并增加了血管化和血管内皮生长因子(VEGF)和内皮细胞标志物 CD31 在损伤生长板中的 mRNA 水平。在体外研究中,NT-3 促进大鼠骨髓基质细胞成骨,诱导 Erk1/2 和 Akt 磷酸化,并增强矿化细胞中 BMPs(特别是 BMP-2)和 VEGF 的表达。它还诱导大鼠原代内皮细胞培养物中 CD31 和 VEGF mRNA 的表达。BMP 活性对 NT-3 的体外成骨作用至关重要,因为其可以通过共添加 BMP 抑制剂 noggin 几乎完全消除。与体内的血管生成作用一致,NT-3 促进跖骨外植体的血管生成,该作用被与抗 VEGF 共同处理所消除。本研究表明,NT-3 可能是骨修复中 BMP-2 和 VEGF 上游的成骨和血管生成因子,需要进一步研究以确定 NT-3 是否可能成为预防生长板骨修复缺陷或促进骨骨折愈合的潜在靶点。